Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Anesthesia
    • CTVS
    • Cardiology
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • Diet and nutrition
    • ENT
    • Gastroenterology
    • Health Dialogues
    • Health News today
    • Health Shorts
    • Health Updates
    • Health video of the day
    • Laboratory Medicine
    • Latest Videos
    • Latest Webinars
    • MD shorts
    • Medical News Today
    • Medical Updates
    • Medical Video of the day
    • Medicine
    • Medico Legal Update
    • Nephrology
    • Neurology and Neurosurgery
    • Obstetrics and Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics & Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Top Videos
    • Urology
Medical Dialogues
  • Medical News
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Medical Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
    • Pharmacy Education News
  • MDTV
      • Anesthesia
      • CTVS
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • Diet and nutrition
      • ENT
      • Gastroenterology
      • Health Dialogues
      • Health News today
      • Health Shorts
      • Health Updates
      • Health video of the day
      • Laboratory Medicine
      • Latest Videos
      • Latest Webinars
      • MD shorts
      • Medical News Today
      • Medical Updates
      • Medical Video of the day
      • Medicine
      • Medico Legal Update
      • Nephrology
      • Neurology and Neurosurgery
      • Obstetrics and Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics & Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Top Videos
      • Urology
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Medical Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
  • Case of the Day
  • Editorial
  • Home
  • Oncology
  • Oncology News
  • Durvalumab...

Durvalumab Significantly Improves Survival for Patients With Biliary Tract Cancer Compared to Chemotherapy Alone

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2022-01-29T09:00:27+05:30  |  Updated On 2022-01-29T09:44:58+05:30
Durvalumab Significantly Improves Survival for Patients With Biliary Tract Cancer Compared to Chemotherapy Alone
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Email
  • koo
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Email
  • koo
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Email
  • koo

Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.Results from a randomized international phase III TOPAZ-1 trial has shown that checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients...

Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.

Results from a randomized international phase III TOPAZ-1 trial has shown that checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs.

The study found that the risk of death was 20% lower in patients who received durvalumab vs placebo. Further the patients who received durvalumab had a 25% lower risk of disease progression or death compared to those who received a placebo. The overall response rate to durvalumab was 26.7% compared to 18.7% for placebo.

The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 20-22, 2022, in San Francisco, California.

Durvalumab is an immune checkpoint inhibitor that blocks the PD-L1 protein on the surface of immune cells, thereby allowing the immune system to recognize and attack tumor cells. Gemcitabine promotes the death of cancer cells that are rapidly dividing. Cisplatin blocks DNA repair mechanisms in cancer cells, leading to their death.

"TOPAZ-1 is the first phase III trial to show that adding immunotherapy to standard chemotherapy can increase survival in biliary tract cancer, and importantly, does so without inducing any new serious side effects," said Do-Youn Oh, MD, PhD, professor in the Division of Medical Oncology, Department of Internal Medicine at Seoul National University Hospital and Seoul National University College of Medicine, and principal investigator in the TOPAZ-1 phase III trial.

It is estimated there were 11,980 new cases of gallbladder cancer diagnosed in the United States (U.S.) in 2021, with an estimated 4,310 deaths1. Patients with biliary tract cancer are often diagnosed when the cancer is already at an advanced stage, which is one of the reasons why survival rates are so low.

Gemcitabine plus cisplatin has been the chemotherapy standard of care for most advanced biliary tract cancers in the U.S. In February 2018, the U.S. Food and Drug Administration approved durvalumab after chemoradiation for unresectable stage III non-small cell lung cancer.

In the study, patients who had not previously been treated for inoperable, locally advanced, recurrent, or metastatic biliary tract cancer were randomly assigned to receive durvalumab or a placebo. All patients also received the current chemotherapy standard of care for the disease, gemcitabine plus cisplatin.

Patients had one of three types of biliary tract cancer: 55% had intrahepatic cancers, which arise in the bile ducts inside the liver; 19 % had extrahepatic cancers, which form outside the liver; and 25% had gallbladder cancer. The trial was conducted in the U.S. and 17 countries, including those in Europe and South America. Nearly 55% of the enrollees were from countries in Asia, including South Korea, Thailand, Japan, and China.

The risk of death for those taking durvalumab was 20% less than those who received the placebo. After a year and a half on the trial, 35.1% of patients who received durvalumab were still alive compared to 25.6% for placebo; at two years, it was 24.9% vs 10.4%, respectively.

Progression-free survival was significantly better with durvalumab compared to placebo, with a 25% lower risk of disease progression for those who received the immunotherapy. The overall response rate (meaning that the cancer regressed more than 30%) to durvalumab was 26.7% compared to 18.7% for the placebo. The most common side effects were anemia (experienced by 48.2% of patients), neutropenia (31.7%) and nausea (40.2%). Potentially serious side effects occurred in 62.7% of patients receiving durvalumab vs 64.9% for placebo, indicating that the majority of side effects in both arms are from chemotherapy.

We are hopeful that durvalumab plus gemcitabine and cisplatin will become a new standard of care for advanced biliary tract cancer," said Dr. Oh. "Our first task at this time is boosting communication with patients and family members about the potential for this immunotherapy combination and what it may mean for their ongoing care."

The researchers are hoping to develop more studies to explore a range of immunotherapy options for biliary tract cancer.

For further reference log on to:


  • DOI

    10.1200/JCO.2022.40.4_suppl.378


Durvalumab Survival Biliary Tract Cancer Chemotherapy TOPAZ-1 trial 
Source : American Society of Clinical Oncology
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as an Editor-in-Chief for the Speciality Medical Dialogues section. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    Dose Escalation of Lenvatinib effective for Differentiated Thyroid Carcinoma, study finds

    Dose Escalation of Lenvatinib effective for Differentiated Thyroid Carcinoma, study finds

    Gut microbes differ in men with prostate cancer

    Gut microbes differ in men with prostate cancer

    High Von Willebrand Factor linked to poor prognosis of breast cancer patients

    High Von Willebrand Factor linked to poor prognosis of breast cancer patients

    Sleep duration linked to increased risk of cancer and related mortality

    Sleep duration linked to increased risk of cancer and related mortality

    Gut microbes differ in men with prostate cancer and those with benign hypertrophy

    Gut microbes differ in men with prostate cancer and those with benign hypertrophy

    New imaging technology less accurate than MRI at detecting prostate cancer, trial shows

    New imaging technology less accurate than MRI at detecting prostate cancer, trial shows

    High-grade Ta tumors unresponsive to BCG progress fast and may be classified as High risk

    High-grade Ta tumors unresponsive to BCG progress fast and may be classified as High risk

    Chest CT not reliable for distinguishing malignant tumors from benign pulmonary anomalies in kids: JAMA

    Chest CT not reliable for distinguishing malignant tumors from benign pulmonary anomalies in kids:...

    Carbon Monoxide Foam may Help Fight Inflammation and stimulate tissue regeneration

    Carbon Monoxide Foam may Help Fight Inflammation and stimulate tissue regeneration

    Mechanism controlling spread of pancreatic cancer discovered by scientists

    Mechanism controlling spread of pancreatic cancer discovered by scientists

    Cancer drug which shows potential as treatment for muscular dystrophy

    Cancer drug which shows potential as treatment for muscular dystrophy

    Additional taxane maintenance therapy fails to  improve survival for women with advanced cancers

    Additional taxane maintenance therapy fails to improve survival for women with advanced cancers

    Western-style diet linked to incident colorectal cancer through intestinal microbiota

    Western-style diet linked to incident colorectal cancer through intestinal microbiota

    Editorial

    Propranolol and essential tremors: A critical review

    Propranolol and essential tremors: A critical review

    Safeguarding Mental Health of Doctors & How They Can Prevent a Burnout

    Safeguarding Mental Health of Doctors & How They Can Prevent a Burnout

    Analyzing the Role of Levofloxacin in Urinary Tract Infections-A review

    Analyzing the Role of Levofloxacin in Urinary Tract Infections-A review

    Management of Allergic Rhinitis during COVID-19 Pandemic

    Management of Allergic Rhinitis during COVID-19 Pandemic

    Role of Probiotics in recurrent bacterial vaginosis: A review

    Role of Probiotics in recurrent bacterial vaginosis: A review

    View All

    Journal Club Today

    AI to help health care staff correctly diagnose alcohol-associated hepatitis, acute cholangitis

    AI to help health care staff correctly diagnose alcohol-associated hepatitis, acute cholangitis

    View All

    Health News Today

    Health Bulletin 6/July/2022

    Health Bulletin 6/July/2022

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X